Identifying Treatment Resistance Related Pathways by Analyzing Serum Extracellular Vesicles of Patients With Resistant Versus Regressed Retinoblastoma

Author:

Manukonda Radhika12,Jakati Saumya34,Attem Jyothi5,Mishra Dilip K.3,Mocherla Tirupathi Rao4,Reddy Mamatha M.6,Gulati Khushboo12,Poluri Krishna Mohan7,Vemuganti Geeta K.5,Kaliki Swathi1

Affiliation:

1. The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, Telangana, India

2. Brien Holden Eye Research Center, L V Prasad Eye Institute, Hyderabad, Telangana, India

3. Ophthalmic Pathology Laboratory, L V Prasad Eye Institute, Hyderabad, Telangana, India

4. Prof. Krothapalli Ravindranath Ophthalmic Research Biorepository, L V Prasad Eye Institute, Hyderabad, Telangana, India

5. School of Medical Sciences, Science Complex, University of Hyderabad, Hyderabad, Telangana, India

6. The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Bhubaneswar, Odisha, India

7. Department of Biosciences and Bioengineering and Centre for Nanotechnology, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand, India

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

Cardiology and Cardiovascular Medicine

Reference46 articles.

1. Bilateral advanced (group D or E) intraocular retinoblastoma: outcomes in 72 Asian Indian patients;Kaliki;Eye (Lond),2019

2. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma;Shields;Arch Ophthalmol,2002

3. The International Classification of Retinoblastoma predicts chemoreduction success;Shields;Ophthalmology,2006

4. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein;Chan;Cancer Res,1997

5. The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells;Zhu;Acta Biochim Biophys Sin (Shanghai),2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3